We Think That There Are Issues Underlying Dezhan Healthcare's (SZSE:000813) Earnings
We Think That There Are Issues Underlying Dezhan Healthcare's (SZSE:000813) Earnings
Despite posting some strong earnings, the market for Dezhan Healthcare Company Limited's (SZSE:000813) stock hasn't moved much. We did some digging, and we found some concerning factors in the details.
尽管德展健康公司(SZSE:000813)发布了一些强劲的盈利数据,但其股票的市场走势并没有出现太大的变化。我们进行了一些调查,并在细节中发现了一些令人担忧的因素。
The Impact Of Unusual Items On Profit
除了稀释之外,还应该注意的是,万集科技在过去12个月中因不寻常项目获得了价值人民币3.5万元的利润。虽然我们希望看到利润增加,但当这些不寻常项目对利润做出重大贡献时,我们会更加谨慎。我们对全球大部分上市公司的数据进行了分析,发现不寻常项目往往是一次性的。这正如我们所期望的那样,因为这些提升被描述为"不寻常"。相对于其利润而言,万集科技在2021年12月前的不寻常项目贡献大。因此,我们可以推断出,这些不寻常项目正在使其财务利润显著增强。
Importantly, our data indicates that Dezhan Healthcare's profit received a boost of CN¥3.0m in unusual items, over the last year. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. And that's as you'd expect, given these boosts are described as 'unusual'. Assuming those unusual items don't show up again in the current year, we'd thus expect profit to be weaker next year (in the absence of business growth, that is).
重要的是,我们的数据显示,过去一年德展健康公司的利润在非常规项目上增加了300万元人民币。我们不能否认,更高的利润通常让我们感到乐观,但我们更希望这种利润是可持续的。当我们对成千上万家上市公司的数字进行分析时,我们发现,在某一年中由于非常规项目的推动,利润通常不会在下一年复发。这是可以理解的,因为这些增长被描述为“非常规”。假设这些非常规项目在当前年度不再出现,我们预计利润在明年将较弱(在没有业务增长的情况下)。
Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Dezhan Healthcare.
注意:我们始终建议投资者检查资产负债表的强度。点击这里查看我们对德展健康的资产负债表分析。
Our Take On Dezhan Healthcare's Profit Performance
我们对德展健康的利润表现的看法
We'd posit that Dezhan Healthcare's statutory earnings aren't a clean read on ongoing productivity, due to the large unusual item. Therefore, it seems possible to us that Dezhan Healthcare's true underlying earnings power is actually less than its statutory profit. On the bright side, the company showed enough improvement to book a profit this year, after losing money last year. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. So while earnings quality is important, it's equally important to consider the risks facing Dezhan Healthcare at this point in time. In terms of investment risks, we've identified 1 warning sign with Dezhan Healthcare, and understanding this should be part of your investment process.
我们认为德展健康的法定盈利并不能准确反映持续生产力,因为有一项较大的非常规项目。因此,我们认为德展健康的真实盈利能力可能低于其法定利润。好消息是,该公司今年实现利润,而去年亏损。但是,如果您想正确了解该公司,就必须考虑更多因素。因此,尽管盈利质量很重要,但同样重要的是考虑当前德展健康所面临的风险。在投资风险方面,我们已经发现了一项德展健康的警示信号,了解这一点应该是您的投资过程的一部分。
Today we've zoomed in on a single data point to better understand the nature of Dezhan Healthcare's profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.
今天,我们将关注一个单一数据点,以更好地了解德展健康利润的性质。但是还有其他很多方法可以了解公司。例如,许多人认为高股本回报率是良好业务经济的指标,而其他人喜欢“跟着钱走”,寻找内部人士正在购买的股票。虽然这可能需要您进行一些研究,但您可能会发现这个免费的公司收藏具有高股本回报率,或者这个持有大量内部人士股份的股票清单很有用。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。